Edition:
United States

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

22.11USD
1:01pm EST
Change (% chg)

$0.33 (+1.52%)
Prev Close
$21.78
Open
$21.71
Day's High
$22.29
Day's Low
$21.71
Volume
19,245
Avg. Vol
99,897
52-wk High
$22.74
52-wk Low
$14.40

Latest Key Developments (Source: Significant Developments)

Amphastar Pharmaceuticals Reports Q3 Adj Non-GAAP EPS Of $0.12
Thursday, 8 Nov 2018 04:10pm EST 

Nov 8 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2018.Q3 REVENUE $75.5 MILLION VERSUS I/B/E/S VIEW $74.7 MILLION.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.12.Q3 GAAP EARNINGS PER SHARE $0.05.Q3 EARNINGS PER SHARE VIEW $0.11 -- THOMSON REUTERS I/B/E/S.  Full Article

Amphastar Pharma Receives FDA Approval For Semi-Purified Heparin
Monday, 4 Jun 2018 06:00am EDT 

June 4 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS RECEIVES FDA APPROVAL FOR SEMI-PURIFIED HEPARIN AT AMPHASTAR NANJING PHARMACEUTICALS.AMPHASTAR PHARMACEUTICALS INC - TO MANUFACTURE HEPARIN SODIUM USP AT CO’S SUBSIDIARY, INTERNATIONAL MEDICATION SYSTEMS LIMITED.  Full Article

Amphastar Pharmaceuticals Reports Q4 Gaap Earnings Per Share $0.03
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS AND FISCAL YEAR ENDED DECEMBER 31, 2017.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.38.Q4 GAAP EARNINGS PER SHARE $0.03.Q4 REVENUE $60.4 MILLION VERSUS I/B/E/S VIEW $60.6 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.  Full Article

Amphastar Pharmaceuticals Reports Q4 GAAP EPS $0.03
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS AND FISCAL YEAR ENDED DECEMBER 31, 2017.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.10 .Q4 GAAP EARNINGS PER SHARE $0.03.Q4 REVENUE $60.4 MILLION VERSUS I/B/E/S VIEW $60.6 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.  Full Article

Amphastar Announces Approval For Sodium Nitroprusside Injection, USP
Tuesday, 19 Dec 2017 06:00am EST 

Dec 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP.AMPHASTAR PHARM - ANTICIPATES LAUNCHING SODIUM NITROPRUSSIDE INJECTION, USP IN Q1 OF 2018.AMPHASTAR PHARMACEUTICALS - FDA GRANTED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR SODIUM NITROPRUSSIDE INJECTION 25MG/ML, 2ML SINGLE DOSE VIAL.  Full Article

Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP
Wednesday, 29 Nov 2017 02:50pm EST 

Nov 29 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP.SAYS AMPHASTAR ANTICIPATES LAUNCHING ITS PRODUCT IN Q1 OF 2018.SAYS U.S. FDA GRANTED APPROVAL OF 2 ABBREVIATED NEW DRUG APPLICATIONS FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION.SAYS APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP 150 MG/ML, 1ML VIAL, & 1ML PREFILLED SYRINGE, RESPECTIVELY.  Full Article

Amphastar Pharma reports results for three months ended Sept
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017.Q3 GAAP earnings per share $0.00.Q3 revenue $57.9 million versus i/b/e/s view $57.2 million.Q3 adjusted non-GAAP earnings per share $0.07.Q3 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.  Full Article

Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection
Wednesday, 20 Sep 2017 04:22pm EDT 

Sept 20 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection.Amphastar Pharmaceuticals Inc - ‍FDA granted approval of co's ANDA for sodium bicarbonate injection 8.4% in 50 ml luer-jet prefilled syringe system​.  Full Article

Amphastar Pharmaceuticals reports Q2 earnings per share $0.04
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Amphastar Pharmaceuticals Inc -:Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017.Q2 adjusted non-gaap earnings per share $0.11.Q2 gaap earnings per share $0.04.Q2 revenue $65.2 million versus I/B/E/S view $63.3 million.Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.Qtrly net revenues of $65.2 million, a decrease of 4% compared to $68.0 million for three months ended june 30, 2016.Q2 earnings per share view $0.07, revenue view $63.3 million -- Thomson Reuters I/B/E/S.  Full Article

Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc
Monday, 24 Jul 2017 06:00am EDT 

July 24 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc.Amphastar Pharmaceuticals - ‍jury found claims of Momenta's U.S. patent to be "invalid for lack of enablement and lack of adequate written description"​.  Full Article